Biological half-life is one of the most practically important properties of a research peptide. It determines how long a compound remains active in a biological system after administration — and it varies enormously between compounds, from under a minute to several hours, based on structural factors that are worth understanding.
This article covers what biological half-life is, what determines it, and reference data for the compounds in the dubaipeptides.ae catalogue where published data exists.
Note: biological half-life (enzymatic clearance in vivo) is an entirely different concept from storage shelf life (chemical stability of a vial in the fridge). These are governed by completely different mechanisms. For storage, see the Peptide Storage Guide →
01 — What Biological Half-Life Means
Biological half-life (t½) is the time required for the concentration of an active compound in a biological system to fall to half its initial value. For peptides, this happens primarily through proteolytic cleavage — enzymes (proteases) in the plasma, liver, kidneys, and target tissues break peptide bonds and inactivate the compound.
The shorter the half-life, the faster a compound is cleared. A compound with a 30-minute half-life has essentially left the system after 3–4 hours. One with a 4-hour half-life may still be measurable 24 hours later.
02 — What Determines It
Peptide Size
Smaller peptides are degraded faster. Tripeptides and tetrapeptides often have half-lives measured in seconds to minutes because protease access is straightforward. Larger peptides (30+ amino acids) have more complex folding that may physically block cleavage sites.
Amino Acid Sequence
Proteases are substrate-specific — they cleave at particular sequence motifs. A peptide rich in proline residues (BPC-157, KPV) is notably resistant because prolyl bonds are cleaved much more slowly by most proteases. Peptides presenting multiple common cleavage motifs are cleared faster.
Terminal Modifications
Unmodified peptides are vulnerable to exopeptidases — enzymes that degrade sequentially from the N- or C-terminus. Two modifications directly extend half-life by blocking these ends:
N-acetylation — blocks aminopeptidase access from the N-terminus
C-terminal amidation — blocks carboxypeptidase access from the C-terminus
Peptides with both modifications (N-Acetyl Selank Amidate, N-Acetyl Semax Amidate) are dramatically more stable in biological environments than their unmodified parents. This is the primary reason these modified forms exist.
Cyclisation
Cyclic peptides — where the termini are joined to form a ring — have no free ends for exopeptidases to attack. Melanotan II and PT-141 are cyclic, and this is a significant contributor to their comparatively longer half-lives.
Route and Distribution
Different administration routes produce different pharmacokinetic profiles. Intravenous injection places compound directly into circulation for immediate plasma exposure. Subcutaneous injection involves absorption from the injection depot, creating a delayed peak and extended presence. Intranasal routes may deliver compound directly to CNS via the olfactory pathway, partially bypassing systemic clearance — particularly relevant for Selank and Semax amidate forms.
03 — Biological Half-Life Reference Table
Published data for research peptides varies by model, route, and measurement method. Values below reflect available peer-reviewed literature and published pharmacokinetic studies. Where human data does not exist, animal model estimates are used and noted.
Compound
Approximate Biological t½
Data Basis
Key Structural Factor
BPC-157
~4 hours
Animal models (rodent)
Proline-rich; exceptional protease resistance for a 15-aa peptide
Thymosin Beta-4 (TB4)
~30–60 min (plasma)
Animal models
Naturally occurring; rapid tissue distribution from plasma
Thymosin Alpha-1 (TA1)
~2 hours
Published pharmacokinetic data
28-aa; relatively stable for its size
GHK-Cu
Minutes to ~30 min
Published studies
Small tripeptide; rapid renal clearance
KPV
Minutes
Extrapolated (tripeptide structure)
Proline residue confers some resistance, but very small size limits t½
Epithalon
~15–30 min
Animal model data
Small tetrapeptide; rapid degradation despite proline
Ipamorelin
~2 hours
Published pharmacokinetic data
Selective GHRP with modified structure; good enzymatic stability
GHRP-6
1–2 hours
Published data
Hexapeptide; partially modified structure
CJC-1295 No DAC
~30 min
Published data
No DAC form; substantially shorter than DAC-modified version
Tesamorelin
~26 min
Published clinical data (Phase III)
GHRH analogue; similar clearance to native GHRH
Melanotan II
~1.5–2 hours
Published studies
Cyclic structure; exopeptidase resistant
PT-141 (Bremelanotide)
~2.7 hours
Published human clinical data
Cyclic; FDA-approved analogue with clinical PK data
MOTS-c
~30–60 min (estimated)
Limited published data (16-aa mitochondrial peptide)
Intracellular origin; plasma pharmacokinetics not fully characterised
SS-31 (Elamipretide)
~2 hours
Published cardiac research data
Tetrapeptide; aromatic residues confer stability
DSIP
30–60 min
Published data
Nonapeptide; moderate stability
KissPeptin-10
~28 min
Published pharmacokinetic data
Decapeptide; rapid cleavage by prolyl endopeptidase
Glutathione
Minutes in plasma
Well-characterised
Rapidly cleaved by gamma-glutamyl transpeptidase; intracellular t½ is longer
Selank (unmodified)
~1–2 min in plasma
Published data
Very short; direct driver of amidate modification development
N-Acetyl Selank Amidate
Significantly extended vs. base Selank
Published comparisons
Terminal modifications block both exopeptidase pathways
N-Acetyl Semax Amidate
Significantly extended vs. base Semax
Published comparisons (analogous to Selank data)
Same dual terminal modification strategy
Values reflect available animal model data and in vitro studies unless otherwise noted. Biological half-life in human systems is not established for most of these compounds.
04 — Implications for Research Protocol Design
Administration timing in in vivo models — a compound with a 30-minute half-life has essentially cleared after 3–4 hours; protocols examining sustained effects must account for this in their design.
Sampling timepoints — blood or tissue samples taken to measure compound concentration or downstream markers must be timed relative to the expected half-life. A sample taken too late relative to administration may show baseline values that do not reflect peak compound activity.
Route selection — subcutaneous administration produces a slower rise to peak concentration and an extended presence versus IV. Intranasal routes for CNS-active peptides like Selank and Semax amidate introduce a different pharmacokinetic profile again.
Protocol frequency — in multi-day protocols, dosing intervals are typically designed relative to half-life. Compounds with very short half-lives (minutes) are often used as single-administration models rather than sustained-dosing protocols in research settings.
The appropriate protocol parameters for any research application should be defined by the study design, the specific compound's known pharmacokinetic properties, and all applicable regulations.
